{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T23:52:10Z","timestamp":1768261930814,"version":"3.49.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T00:00:00Z","timestamp":1538697600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.02313","type":"journal-article","created":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T00:14:07Z","timestamp":1538698447000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Development of a Stable MGAT1\u2212 CHO Cell Line to Produce Clade C gp120 With Improved Binding to Broadly Neutralizing Antibodies"],"prefix":"10.3389","volume":"9","author":[{"given":"Rachel C.","family":"Doran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara M.","family":"O'Rourke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennie M.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn A.","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip W.","family":"Berman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,10,5]]},"reference":[{"key":"B1","unstructured":"W125938349Aids152001"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1126\/science.1178746","article-title":"Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target","volume":"326","author":"Walker","year":"2009","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/nature10696","article-title":"Structure of HIV-1 gp120 V1\/V2 domain with broadly neutralizing antibody PG9","volume":"480","author":"McLellan","year":"2011","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/nsmb.2594","article-title":"Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120","volume":"20","author":"Kong","year":"2013","journal-title":"Nat Struct Mol Biol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"236ra63","DOI":"10.1126\/scitranslmed.3008104","article-title":"Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV","volume":"6","author":"Sok","year":"2014","journal-title":"Sci Transl Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"13800","DOI":"10.1073\/pnas.1006498107","article-title":"Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens","volume":"107","author":"Doores","year":"2010","journal-title":"Proc Natl Acad Sci USA."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e43903","DOI":"10.1371\/journal.pone.0043903","article-title":"Glycoform and net charge heterogeneity in gp120 immunogens used in HIV vaccine trials","volume":"7","author":"Yu","year":"2012","journal-title":"PLoS ONE"},{"key":"B10","doi-asserted-by":"publisher","first-page":"7479","DOI":"10.1038\/ncomms8479","article-title":"Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies","volume":"6","author":"Pritchard","year":"2015","journal-title":"Nat Commun."},{"key":"B11","doi-asserted-by":"publisher","first-page":"10510","DOI":"10.1128\/JVI.00552-10","article-title":"Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16","volume":"84","author":"Doores","year":"2010","journal-title":"J Virol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e2005817","DOI":"10.1371\/journal.pbio.2005817","article-title":"CRISPR\/Cas9 gene editing for the creation of an MGAT1 deficient CHO cell line to control HIV-1 vaccine glycosylation","volume":"16","author":"Byrne","year":"2018","journal-title":"PLoS Biol."},{"key":"B13","first-page":"S277","article-title":"Development of bivalent rgp120 vaccines to prevent HIV type 1 infection","volume":"14","author":"Berman","year":"1998","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1097\/01.qai.0000136091.72955.4b","article-title":"Phase I\/II study of a candidate vaccine designed against the B and E subtypes of HIV-1","volume":"37","author":"Pitisuttithum","year":"2004","journal-title":"J Acquir Immune Defic Syndr."},{"key":"B15","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1086\/428404","article-title":"Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection","volume":"191","author":"Flynn","year":"2005","journal-title":"J Infect Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e0157391","DOI":"10.1371\/journal.pone.0157391","article-title":"Generation and characterization of a bivalent HIV-1 subtype C gp120 protein boost for proof-of-concept HIV vaccine efficacy trials in Southern Africa","volume":"11","author":"Zambonelli","year":"2016","journal-title":"PLoS ONE"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e12076","DOI":"10.1371\/journal.pone.0012076","article-title":"Comparative immunogenicity of HIV-1 clade C envelope proteins for prime\/boost studies","volume":"5","author":"Smith","year":"2010","journal-title":"PLoS ONE"},{"key":"B18","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.immuni.2012.11.011","article-title":"Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2","volume":"38","author":"Liao","year":"2013","journal-title":"Immunity"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.1128\/JVI.02297-12","article-title":"Antigenicity and immunogenicity of transmitted\/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1","volume":"87","author":"Liao","year":"2013","journal-title":"J Virol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1093\/bioinformatics\/bts199","article-title":"Geneious basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data","volume":"28","author":"Kearse","year":"2012","journal-title":"Bioinformatics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e0197656","DOI":"10.1371\/journal.pone.0197656","article-title":"Robotic selection for the rapid development of stable CHO cell lines for HIV vaccine for production","volume":"13","author":"O'Rourke","year":"2018","journal-title":"PLoS ONE"},{"key":"B22","doi-asserted-by":"publisher","first-page":"16952","DOI":"10.1038\/srep16952","article-title":"CMV promoter mutants with a reduced propensity to productivity loss in CHO cells","volume":"5","author":"Moritz","year":"2015","journal-title":"Sci Rep"},{"key":"B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/viro.1999.0031","article-title":"Development of bivalent (B\/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand","volume":"265","author":"Berman","year":"1999","journal-title":"Virology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0196370","DOI":"10.1371\/journal.pone.0196370","article-title":"Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies","volume":"13","author":"Doran","year":"2018","journal-title":"PLoS ONE"},{"key":"B25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.molimm.2014.06.025","volume":"62","author":"Doran","year":"2014","journal-title":"Mol Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.it.2014.08.007","article-title":"Antibody B cell responses in HIV-1 infection","volume":"35","author":"Mouquet","year":"2014","journal-title":"Trends Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.molimm.2016.07.003","article-title":"Fragments of the V1\/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PG9 antibody","volume":"77","author":"Morales","year":"2016","journal-title":"Mol Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"E17","DOI":"10.3390\/vaccines4020017","article-title":"Comprehensive characterization of reference standard lots of HIV-1 Subtype C Gp120 proteins for clinical trials in Southern African Regions","volume":"4","author":"Wang","year":"2016","journal-title":"Vaccines"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.1213256","article-title":"A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan","volume":"334","author":"Pejchal","year":"2011","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science"},{"key":"B31","doi-asserted-by":"publisher","first-page":"E3268","DOI":"10.1073\/pnas.1217207109","article-title":"Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies","volume":"109","author":"Mouquet","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B32","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nature10373","article-title":"Broad neutralization coverage of HIV by multiple highly potent antibodies","volume":"477","author":"Walker","year":"2011","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/0264-410X(95)00019-W","article-title":"Efficient purification and rigorous characterisation of a recombinant gp120 for HIV vaccine studies","volume":"13","author":"Jones","year":"1995","journal-title":"Vaccine"},{"key":"B34","doi-asserted-by":"publisher","first-page":"7038","DOI":"10.1021\/bi012168i","article-title":"Beta-turn Phe in HIV-1 Env binding site of CD4 and CD4 mimetic miniprotein enhances Env binding affinity but is not required for activation of co-receptor\/17b site","volume":"41","author":"Dowd","year":"2002","journal-title":"Biochemistry"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1128\/JVI.76.6.2835-2847.2002","article-title":"Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus","volume":"76","author":"Srivastava","year":"2002","journal-title":"J Virol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1080\/21645515.2017.1380137","article-title":"Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines","volume":"13","author":"Wang","year":"2017","journal-title":"Hum Vaccin Immunother."},{"key":"B37","doi-asserted-by":"publisher","first-page":"8245","DOI":"10.1128\/JVI.00628-15","article-title":"Comparative analysis of the glycosylation profiles of membrane-anchored HIV-1 envelope glycoprotein trimers and soluble gp140","volume":"89","author":"Go","year":"2015","journal-title":"J Virol."},{"key":"B38","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1089\/aid.1993.9.1233","article-title":"Nonaffinity purification of recombinant gp120 for use in AIDS vaccine development","volume":"9","author":"Scandella","year":"1993","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B39","article-title":"editor Strategies for Improving the AIDSVAX Vaccines","volume-title":"NIAID HIV Env Manufacturing Workshop","author":"PW","year":"2015"},{"key":"B40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.coi.2016.05.011","article-title":"New concepts in HIV-1 vaccine development","volume":"41","author":"Stephenson","year":"2016","journal-title":"Curr Opin Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"Pe366","DOI":"10.1016\/S2352-3018(18)30071-7","article-title":"Subtype C ALVAC-HIV and bivalent subtype C gp120\/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1\/2 trial","volume":"5","author":"Bekker","year":"2018","journal-title":"Lancet"},{"key":"B42","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1073\/pnas.1620788114","article-title":"Effectiveness of UNAIDS targets and HIV vaccination across 127 countries","volume":"114","author":"Medlock","year":"2017","journal-title":"Proc Nat Acad Sci USA"},{"key":"B43","doi-asserted-by":"publisher","first-page":"20526","DOI":"10.1074\/jbc.M114.554089","article-title":"HIV-1 envelope proteins and V1\/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1","author":"Morales","year":"2014","journal-title":"J Biol Chem"},{"key":"B44","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1126\/science.1192819","article-title":"Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01","volume":"329","author":"Zhou","year":"2010","journal-title":"Science"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1126\/science.120753","article-title":"Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing","volume":"333","author":"Wu","year":"2011","journal-title":"Science"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e1003618","DOI":"10.1371\/journal.ppat.1003618","article-title":"A next-generation cleaved, soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies","volume":"9","author":"Sanders","year":"2013","journal-title":"PLoS Pathog."},{"key":"B47","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1126\/science.1234150","article-title":"Rational HIV immunogen design to target specific germline B cell receptors","volume":"340","author":"Jardine","year":"2013","journal-title":"Science"},{"key":"B48","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.immuni.2016.08.016","article-title":"HIV Vaccine design to target germline precursors of glycan-dependent broadly neutralizing antibodies","volume":"45","author":"Steichen","year":"2016","journal-title":"Immunity"},{"key":"B49","doi-asserted-by":"publisher","first-page":"7933","DOI":"10.1128\/JVI.79.12.7933-7937.2005","article-title":"Enhanced Immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1","volume":"79","author":"Wang","year":"2005","journal-title":"J Virol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e01077","DOI":"10.1128\/JVI.01077-17","article-title":"HIV-1 gp120 and modified vaccinia virus ankara (MVA) gp140 boost immunogens increase immunogenicity of a DNA\/MVA HIV-1 Vaccine","volume":"91","author":"Shen","year":"2017","journal-title":"J Virol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nrmicro3360","article-title":"Novel vaccine vectors for HIV-1","volume":"12","author":"Barouch","year":"2014","journal-title":"Nat Rev Microbiol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"11007","DOI":"10.1128\/JVI.01409-16","article-title":"Rationally designed immunogens targeting HIV-1 gp120 V1V2 induce distinct conformation-specific antibody responses in rabbits","volume":"90","author":"Jiang","year":"2016","journal-title":"J Virol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02313\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T00:14:35Z","timestamp":1538698475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02313\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,5]]},"references-count":52,"alternative-id":["10.3389\/fimmu.2018.02313"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.02313","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,5]]},"article-number":"2313"}}